NCT01249677已完成4 期
Chronic Reduction of Fasting Gylcaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
Ruhr University of Bochum1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Improvements in first and second phase insulin secretion
研究概览
简要总结
Glucose-induced insulin secretion is often diminished in hyperglycaemic patients with type 2 diabetes. The investigators examined, whether chronic basal insulin treatment with insulin glargine lead to improvements in glucose-induced insulin secretion.
详细描述
14 patients with type 2 diabetes on previous metformin therapy were examined before and after eight weeks of treatment with insulin glargine, aimed to normalize fasting glycaemia. Intravenous glucose tolerance tests were performed with and without previous adjustment of fasting glucose levels by means of a 3-hour intravenous insulin infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 75 years, inclusive
- •BMI-range 27-50 kg/m²
- •patients with type 2 diabetes presenting with fasting hyperglycaemia (>126mg/dl) on metformin treatment
排除标准
- •1.Pre-existing insulin therapy, treatment with sulphonylureas, glitazones, 2.glinides, DPP-4-inhibitors or exenatide 3.patients with type 1 diabetes 4.Patients are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral contraceptives, sexual abstinence or vasectomised partner). A male subject who is sexually active and has not been surgically sterilised must be informed that he must either use a condom during intercourse, ensure that his partner practices contraception, or he must refrain from sexual intercourse during the trial and until 1 month after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by trial medication. It is strongly recommended that the female partners use a highly effective contraception (Pearl Index < 1%).
- •Patients have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days prior to screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
- •Patients have alcohol consumption (>20 g daily for males and >10 g daily for females)
- •Patients have alanine aminotransaminase (ALT) greater than ten times the upper limit of the reference range.
- •9.Patients are undergoing therapy for a malignancy, other than basal cell or squamous cell skin cancer.
- •Patients have cardiac disease that is Class III or IV, according to the New York Heart Association criteria.
- •Patients have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine >1.8 mg/dL for males and greater than or equal to >1.5 mg/dL for females. 12.Patients have known hemoglobinopathy or chronic anemia 13.Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
- •Patients have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes them from following and completing the protocol, in the opinion of the investigator.
- •Patients fail to satisfy the investigator of suitability to participate for any other reason.
研究组 & 干预措施
insulin glargine
Experimental
patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
干预措施: insulin glargine (Drug)
结局指标
主要结局
Improvements in first and second phase insulin secretion
时间窗: 8 weeks
Improvements in first and second phase insulin secretion after bedtime administration of insulin glargin, titrated to reach normal (90-100 mg/dl) fasting glucose levels
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Crossover Study to Assess the 2 Glucose Tolerance Tests on Incretin, Beta-cell function and Insulin Sensitivity in Japanese Healthy and Type 2 Diabetes SubjectsT2DMJPRN-UMIN000014575Kansai Electric Power Hospital32
已完成
不适用
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 DiabetesType 2 DiabetesNCT02669524University Hospital, Gentofte, Copenhagen20
已完成
不适用
Beta-Cell Function After Near-Normalisation of Blood GlucoseType 2 DiabetesNCT00612950Hvidovre University Hospital8
已完成
1 期
The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIPType 2 DiabetesNCT02673554Diabeteszentrum Bad Lauterberg im Harz30
已完成
不适用
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose ToleranceDeteriorated Glucose HomeostasisInactivityInsulin ResistanceNCT01173978Glostrup University Hospital, Copenhagen10